Incidence of Diabetic Ketoacidosis in Dapagliflozin-Treated Japanese Patients With Type 1 Diabetes Mellitus: An Observational Cohort Database Study.

ABSTRACT:

Purpose

Diabetic ketoacidosis (DKA) is an important identified risk of treatment with the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin, particularly in patients with type 1 diabetes mellitus (T1DM). We evaluated the DKA incidence rate (IR) among dapagliflozin-treated Japanese patients with T1DM receiving concomitant insulin.

Methods

This observational, cohort, post-marketing study utilized data from the JMDC Payer database. All patients had T1DM and were prescribed insulin; the dapagliflozin group included dapagliflozin-treated patients and the control group included SGLT2i nonusers. The study outcomes were DKA events (a composite of DKA resulting in hospitalization and/or death). Using a prevalent new-user design, time-stratified sequential propensity sco

SUBMITTER: Tamura R 

PROVIDER: S-EPMC12741505 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature